Driver Gene Detection Through Bayesian Network Integration of Mutation and Expression Profiles

Overview

Journal Bioinformatics

Publisher Oxford University Press

Specialty Biology

Date 2022 May 13

PMID 35561191

Authors

Zhong Chen

You Lu

Bo Cao

Wensheng Zhang

Andrea Edwards

Kun Zhang

Affiliations

Soon will be listed here.

Abstract

Motivation: The identification of mutated driver genes and the corresponding pathways is one of the primary goals in understanding tumorigenesis at the patient level. Integration of multi-dimensional genomic data from existing repositories, e.g., The Cancer Genome Atlas (TCGA), offers an effective way to tackle this issue. In this study, we aimed to leverage the complementary genomic information of individuals and create an integrative framework to identify cancer-related driver genes. Specifically, based on pinpointed differentially expressed genes, variants in somatic mutations and a gene interaction network, we proposed an unsupervised Bayesian network integration (BNI) method to detect driver genes and estimate the disease propagation at the patient and/or cohort levels. This new method first captures inherent structural information to construct a functional gene mutation network and then extracts the driver genes and their controlled downstream modules using the minimum cover subset method.

Results: Using other credible sources (e.g. Cancer Gene Census and Network of Cancer Genes), we validated the driver genes predicted by the BNI method in three TCGA pan-cancer cohorts. The proposed method provides an effective approach to address tumor heterogeneity faced by personalized medicine. The pinpointed drivers warrant further wet laboratory validation.

Availability And Implementation: The supplementary tables and source code can be obtained from https://xavieruniversityoflouisiana.sharefile.com/d-se6df2c8d0ebe4800a3030311efddafe5.

Supplementary Information: Supplementary data are available at Bioinformatics online.

References

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Sondka Z, Bamford S, Cole C, Ward S, Dunham I, Forbes S . The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018; 18(11):696-705. PMC: 6450507. DOI: 10.1038/s41568-018-0060-1. View

Muniyan S, Chen S, Lin F, Wang Z, Mehta P, Batra S . ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cell Signal. 2015; 27(11):2261-71. PMC: 4565757. DOI: 10.1016/j.cellsig.2015.08.002. View

Pihur V, Datta S, Datta S . RankAggreg, an R package for weighted rank aggregation. BMC Bioinformatics. 2009; 10:62. PMC: 2669484. DOI: 10.1186/1471-2105-10-62. View

Dong C, Guo Y, Yang H, He Z, Liu X, Wang K . iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes. Genome Med. 2016; 8(1):135. PMC: 5180414. DOI: 10.1186/s13073-016-0390-0. View

Watson I, Takahashi K, Futreal P, Chin L . Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013; 14(10):703-18. PMC: 4014352. DOI: 10.1038/nrg3539. View

Croft D, OKelly G, Wu G, Haw R, Gillespie M, Matthews L . Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2010; 39(Database issue):D691-7. PMC: 3013646. DOI: 10.1093/nar/gkq1018. View

Artez A, Bernabe R, Eerola I, Hemsley F, Jennings J, Kerr D . International network of cancer genome projects. Nature. 2010; 464(7291):993-8. PMC: 2902243. DOI: 10.1038/nature08987. View

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T . MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget. 2016; 8(5):7964-7976. PMC: 5352374. DOI: 10.18632/oncotarget.13860. View

10.

Schaefer C, Anthony K, Krupa S, Buchoff J, Day M, Hannay T . PID: the Pathway Interaction Database. Nucleic Acids Res. 2008; 37(Database issue):D674-9. PMC: 2686461. DOI: 10.1093/nar/gkn653. View

11.

Wei X, Walia V, Lin J, Teer J, Prickett T, Gartner J . Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011; 43(5):442-6. PMC: 3161250. DOI: 10.1038/ng.810. View

12.

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

13.

Guo W, Zhang S, Liu L, Liu F, Shi Q, Zhang L . Discovering personalized driver mutation profiles of single samples in cancer by network control strategy. Bioinformatics. 2018; 34(11):1893-1903. DOI: 10.1093/bioinformatics/bty006. View

14.

Edlind M, Hsieh A . PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014; 16(3):378-86. PMC: 4023363. DOI: 10.4103/1008-682X.122876. View

15.

Hou J, Ma J . DawnRank: discovering personalized driver genes in cancer. Genome Med. 2014; 6(7):56. PMC: 4148527. DOI: 10.1186/s13073-014-0056-8. View

16.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

17.

Song J, Peng W, Wang F . A random walk-based method to identify driver genes by integrating the subcellular localization and variation frequency into bipartite graph. BMC Bioinformatics. 2019; 20(1):238. PMC: 6518800. DOI: 10.1186/s12859-019-2847-9. View

18.

Kypta R, Waxman J . Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012; 9(8):418-28. DOI: 10.1038/nrurol.2012.116. View

19.

Przytycki P, Singh M . Differential analysis between somatic mutation and germline variation profiles reveals cancer-related genes. Genome Med. 2017; 9(1):79. PMC: 5574113. DOI: 10.1186/s13073-017-0465-6. View

20.

Ling X, Chen Z, Luo H, Liu Z, Liang Y, Chen G . BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett. 2016; 11(3):2001-2008. PMC: 4774446. DOI: 10.3892/ol.2016.4161. View